Bio-Rad Laboratories, Inc. BIO
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +18.45%
- 1 year
- +18.21%
5D +1.40 (+0.39%)
- Market cap
- 9.65B
- Revenue (ttm)
- 2.59B
- Profit margin
- 39.45%
- EPS (ttm)
- 37.64
- Shares out
- 21.83M
- P/E ratio
- 9.54
- Forward P/E
- 36.19
- YTD return
- +18.45%
- 1-year return
- +18.21%
- 50-day average
- 371.83
- Volume
- 182.30K
- Avg volume
- 260.18K
- Open
- 364.34
- Previous close
- 367.50
- Day's range
- 353.31 – 369.44
- 52-week range
- 236.73 – 396.23
- Beta
- 1.06
- Analysts
- Hold
- Price target
- 356.67 (-0.6%)
- Earnings date
- Feb 11, 2027
Key statistics
- 200-day average
- 318.29
- Enterprise value
- 9.58B
- PEG ratio
- 4.01
- Price / sales
- 3.72
- Price / book
- 1.27
- Revenue growth
- 0.50%
- Free cash flow
- 271.65M
- Total cash
- 1.66B
- Total debt
- 1.36B
- Return on equity
- 14.27%
- Short % of float
- 7.21%
Fundamental scorecard
11 of 25 checks passed on BIO’s reported financials
11of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 2 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 280.00
- Target (mean)
- 356.67
- Target (high)
- 440.00
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 2.83.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 2.83 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 2.23 | 2.65 | +0.42 | +18.83% |
| Aug 4, 2026 | Jun 30, 2026 | 1.75 | 2.62 | +0.87 | +49.71% |
| Apr 30, 2026 | Mar 31, 2026 | 1.97 | 1.89 | -0.08 | -4.06% |
| Feb 12, 2026 | Dec 31, 2025 | 2.57 | 2.51 | -0.06 | -2.33% |
| Oct 29, 2025 | Sep 30, 2025 | 2.30 | 2.26 | -0.04 | -1.74% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Citigroup | main | Neutral | Neutral |
| Aug 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 5, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 1, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bio-rad.com
News
David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
Insider Selling: Bio-Rad Laboratories (NYSE:BIO) EVP Sells $539,882.00 in Stock
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Courtney Enloe Sells 902 Shares
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider Jonathan Divincenzo Sells 919 Shares
Bio-Rad Laboratories (NYSE:BIO) Stock: Insider James Barry Sells 1,400 Shares
Bio-Rad Laboratories, Inc. $BIO Stock Sold by Fisher Asset Management LLC
BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440
Bio-Rad Laboratories Q3 2026 Earnings Call Transcript Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B Est
Your note
Sign in to keep a note on BIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLISON SCHWARTZ | Director | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,734 |
| COREY COLLEEN | Officer | Conversion of Exercise of derivative security | Sep 4, 2025 | 19,550 |
| CROWLEY MICHAEL W | Officer | Conversion of Exercise of derivative security | Mar 13, 2025 | 8,171 |
| DIVINCENZO JONATHAN P | President | Sale | Nov 8, 2026 | 1,962 |
| ENGELHARDT EVA ANETTE | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 1,828 |
| EVRAN SEDAT | Officer | Conversion of Exercise of derivative security | Oct 19, 2026 | 4,160 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Investment Management, LLC | 11.25% | 2,455,580 | 880.28M | Sep 29, 2026 |
| Blackrock Inc. | 7.97% | 1,740,336 | 623.88M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 4.06% | 885,977 | 317.61M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.79% | 827,202 | 296.54M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 3.72% | 811,564 | 290.93M | Sep 29, 2026 |
| Ariel Investments, LLC | 3.62% | 789,341 | 282.96M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Eagle Funds-First Eagle Global Fund | 8.61% | 1,878,739 | 673.49M | Jul 30, 2026 |
| SmallCap World Fund Inc | 4.26% | 930,906 | 333.71M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.97% | 648,604 | 232.51M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.68% | 584,782 | 209.63M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.94% | 423,193 | 151.71M | Jun 29, 2026 |
| Ariel Investment Trust-Ariel Fund | 1.55% | 338,204 | 121.24M | Sep 29, 2026 |
